CoChat
Sign Up
Cited by 135Substance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on BehaviorAlcohol Consumption and Health Effects

Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: Temporal effects of drinking

Anton, Raymond F., Drobes, David J., Voronin, Konstantin, Durazo-Avizu, Ramon, Moak, Darlene·2004·Psychopharmacology
DOI 10.1007/s00213-003-1720-7
Open this paper in CoChat — free account

Abstract

Background This clinical laboratory study evaluated how the timing of drinking and subjective responses to alcohol are effected by the opioid antagonist naltrexone.Methods Forty non-treatment seeking alcoholics were randomly assigned to treatment with 50 mg naltrexone or matching placebo for 7 days. On day 7, they were administered an "initial drink" of alcohol (blood alcohol levels of between 20 and 30 mg%) in a bar-like setting. In a random fashion, half of the subjects in each group (naltrexone and placebo) had either immediate or delayed (40 min) access to up to 8 additional mini-drinks over a 2-h period. In the delayed group subjective reactions to alcohol were measured prior to access to more drinks.Results In the immediate access condition, subjects had similar drinking patterns, irrespective of whether they were taking naltrexone or placebo. However, in the delayed condition, naltrexone-treated subjects consumed fewer drinks and had a slower progression of drinking. There was a positive relationship between alcohol-induced stimulation and the number of drinks consumed in the placebo subjects but a negative correlation in the naltrexone subjects.Conclusions These data suggest that the effectiveness of naltrexone on alcohol consumption may be somewhat dependent on pattern of consumption. Since naltrexone seems to disrupt the connection between alcohol-induced stimulation and further alcohol consumption, there may be a time-critical period between drinks necessary for alcoholics to benefit from its effects. These findings are consistent with clinical trial data that suggest a potential synergistic effect between relapse prevention therapies and opiate antagonist pharmacotherapy.

Integrity signals

Registry

Crossref · 10.1007/s00213-003-1720-7

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Altering euphoric and pleasurable effects of alcohol is hypothesized to underlie in part the efficacy of opioid receptor antagonists, including naltrexone and nalmefene.

    “The findings may have relevance to medication development, as altering euphoric and pleasurable effects of alcohol would be important targets for novel treatments and are hypothesized to underlie in part the efficacy of opioid receptor antagonists, including naltrexone and nalmefene(67–76).”

    From A Prospective 5-Year Re-examination of Alcohol Response in Heavy Drinkers Progressing in Alcohol Use Disorder (2016) · cites this paper as [75]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Anton, R. F., Drobes, D. J., Voronin, K., Durazo-Avizu, R., & Moak, D.
Affiliations
  • Medical University of South Carolina (US)
  • University of South Florida (US)
  • Northwestern University (US)
Corresponding author
Anton, Raymond F.
ORCID
Venue
Psychopharmacology
Publisher
Springer Science and Business Media LLC
Published
2004-04-01
Volume
173
Issue
1-2
Pages
32-40
ISSN
  • 0033-3158 (ISSN-L)
  • 1432-2072
DOI
10.1007/s00213-003-1720-7
OpenAlex
W2092120977
Cited by
135
References
37
Citations by year
2025: 1 · 2023: 3 · 2022: 8 · 2021: 3 · 2020: 3 · 2019: 3 · 2017: 5 · 2016: 7 · 2015: 9 · 2014: 11 · 2013: 7 · 2012: 15
FWCI
4.77
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Psychopharmacology (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Medical University of South Carolina
  • National Institute on Alcohol Abuse and Alcoholism (P50AA010761)
Topics
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
Keywords
naltrexone, alcohol consumption, alcoholism, opioid antagonists, relapse prevention, treatment seeking
MeSH terms
Adult, Aged, Alcohol Drinking, Ethanol, Alcoholism, Analysis of Variance, Central Nervous System Depressants, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Time Factors, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review